Legal & General Group
PRLD icon

Legal & General Group’s Prelude Therapeutics PRLD Stock Holding History

Legal & General Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-962
Closed -$739 – 3508
2025
Q1 		$739 Hold
962
– – ﹤0.01% 3373
2024
Q4 		$1.23K Hold
962
– – ﹤0.01% 3386
2024
Q3 		$1.99K Hold
962
– – ﹤0.01% 3399
2024
Q2 		$3.67K Hold
962
– – ﹤0.01% 3394
2024
Q1 		$4.56K Hold
962
– – ﹤0.01% 3307
2023
Q4 		$4.11K Hold
962
– – ﹤0.01% 3339
2023
Q3 		$2.97K Hold
962
– – ﹤0.01% 3390
2023
Q2 		$4.33K Buy
+962
New +$5.75K ﹤0.01% 3378
2022
Q2 		– Sell
-3,914
Closed -$27K – 3625
2022
Q1 		$27K Hold
3,914
– – ﹤0.01% 3156
2021
Q4 		$49K Buy
3,914
+956
+32% +$15.6K ﹤0.01% 3037
2021
Q3 		$92K Buy
2,958
+1,841
+165% +$59.6K ﹤0.01% 2872
2021
Q2 		$32K Buy
1,117
+69
+7% +$2.46K ﹤0.01% 3114
2021
Q1 		$45K Buy
1,048
+44
+4% +$2.92K ﹤0.01% 2845
2020
Q4 		$72K Sell
1,004
-60,485
-98% -$3.01M ﹤0.01% 2684
2020
Q3 		$1.85M Buy
+61,489
New +$1.74M ﹤0.01% 1791

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group's PRLD Position: Q2 2025 in Review

Legal & General Group sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 962 shares — an estimated $739 sold.

Legal & General Group first reported a position in PRLD in Q3 2020 and held it in 15 quarters. The position peaked at $1.85M in Q3 2020. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Legal & General Group reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 962 Prelude Therapeutics shares in Q2 2025, an estimated $739.
  • Legal & General Group first reported a position in Prelude Therapeutics in Q3 2020 and held it in 15 quarters.
  • Legal & General Group's Prelude Therapeutics position peaked at $1.85M in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.